# JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

> **NCT06675422** · PHASE1,PHASE2 · RECRUITING · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 20 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** JY231 injection

## Key facts

- **NCT ID:** NCT06675422
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675422, "JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06675422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*